---
title: Stakeholders in healthcare innovation
videoId: GLjKn61fJBw
---

From: [[oecdobservatoryofpublicsec3116]] <br/> 

Healthcare innovation, particularly in complex areas like cancer, necessitates a broad range of stakeholders working together to achieve significant societal impact. The problem of cancer is inherently complex, involving many parties, and requires a collaborative approach across [[multistakeholder_engagement_in_innovation_ecosystems|multiverse stakeholders]] with clear goals and reasonable timeframes <a class="yt-timestamp" data-t="04:58:00">[04:58:00]</a>. No single actor can solve these challenges alone <a class="yt-timestamp" data-t="06:27:00">[06:27:00]</a>.

## The Need for Collaboration

A mission-oriented approach is crucial for healthcare innovation, providing directionality, shared understanding, and commitment among diverse actors <a class="yt-timestamp" data-t="05:21:00">[05:21:00]</a>. This approach integrates systemic aspects of innovation, including technology, infrastructure, behavior, and policy <a class="yt-timestamp" data-t="06:17:00">[06:17:00]</a>. It addresses fragmentation in research, healthcare, and education <a class="yt-timestamp" data-t="10:21:00">[10:21:00]</a>.

## Key Stakeholders

The most significant opportunities in healthcare innovation, such as personalized medicine for cancer patients, arise where multi-sectoral knowledge, experience, and decision-making power converge <a class="yt-timestamp" data-t="08:41:00">[08:41:00]</a>. A "penta-helix" model is often applied, involving:
*   Academia <a class="yt-timestamp" data-t="18:42:00">[18:42:00]</a>
*   Healthcare providers <a class="yt-timestamp" data-t="18:42:00">[18:42:00]</a>
*   Patients <a class="yt-timestamp" data-t="18:42:00">[18:42:00]</a>
*   Authorities (government/regulators) <a class="yt-timestamp" data-t="18:48:00">[18:48:00]</a>
*   Industry <a class="yt-timestamp" data-t="18:52:00">[18:52:00]</a>

This broader partnership can also include "unusual partners" such as ministries of economy or transport, or local authorities, especially when addressing issues like access to care due to lack of transport <a class="yt-timestamp" data-t="25:52:00">[25:52:00]</a>. For prevention efforts, cooperation with education sectors and schools is essential to raise awareness and improve health literacy <a class="yt-timestamp" data-t="27:13:00">[27:13:00]</a>.

## Challenges in [[engaging_stakeholders_in_innovation|Engaging Stakeholders]]

Despite the recognized need for collaboration, bringing diverse stakeholders together faces several challenges:
*   **Cultural Differences** <a class="yt-timestamp" data-t="19:09:00">[19:09:00]</a>: Partners, especially from academia and industry, may not be accustomed to working closely together, often harboring distrust or focusing on individual goals (e.g., Nobel Prize vs. product development) <a class="yt-timestamp" data-t="23:55:00">[23:55:00]</a>. Industry players themselves may not be used to collaborating with competitors <a class="yt-timestamp" data-t="00:45:00">[00:45:00]</a>.
*   **Fragmentation** <a class="yt-timestamp" data-t="10:21:00">[10:21:00]</a>: Health systems, research, and education are often fragmented, hindering a cohesive approach <a class="yt-timestamp" data-t="10:21:00">[10:21:00]</a>.
*   **Regulatory Concerns** <a class="yt-timestamp" data-t="29:08:00">[29:08:00]</a>: Regulatory agencies may be reluctant to partner with companies they regulate, posing challenges for policy development <a class="yt-timestamp" data-t="29:08:00">[29:08:00]</a>.
*   **Funding and Reimbursement Models** <a class="yt-timestamp" data-t="30:33:00">[30:33:00]</a>: Innovation funding is often project-based and short-term, lacking the long-term perspective needed for sustainable change <a class="yt-timestamp" data-t="30:37:00">[30:37:00]</a>. Holistic and sustainable reimbursement models are needed to understand societal benefits <a class="yt-timestamp" data-t="30:54:00">[30:54:00]</a>.
*   **Data Management** <a class="yt-timestamp" data-t="33:13:00">[33:13:00]</a>: Issues include data quality, standards, access, protection, and cybersecurity <a class="yt-timestamp" data-t="33:20:00">[33:20:00]</a>. Integrating genetics information into routine healthcare also presents a challenge <a class="yt-timestamp" data-t="34:32:00">[34:32:00]</a>.
*   **Implementation Gaps** <a class="yt-timestamp" data-t="16:07:00">[16:07:00]</a>: A disconnect often exists between health policy and implementation science, particularly concerning administrative routines and annual budget cycles <a class="yt-timestamp" data-t="38:46:00">[38:46:00]</a>.
*   **Patient Involvement** <a class="yt-timestamp" data-t="36:31:00">[36:31:00]</a>: While patients are at the heart of care, effectively involving a representative group of patients, providing necessary resources, and allowing them to contribute meaningfully requires specific methodologies, not just good intentions <a class="yt-timestamp" data-t="36:41:00">[36:41:00]</a>.

## Strategies for Effective Stakeholder Engagement

Successful stakeholder engagement and collaboration require several key ingredients:
*   **Trust and Communication** <a class="yt-timestamp" data-t="17:13:00">[17:13:00]</a>: Building trust is crucial and demands hard work, joint discussions, and shared vision development <a class="yt-timestamp" data-t="24:20:00">[24:20:00]</a>. Open and transparent communication among all parties helps avoid repetition and effectively uses resources <a class="yt-timestamp" data-t="42:36:00">[42:36:00]</a>.
*   **Common Vision and Co-ownership** <a class="yt-timestamp" data-t="17:16:00">[17:16:00]</a>: Aligning around a shared mission makes collaboration easier and encourages co-ownership of actions and problems <a class="yt-timestamp" data-t="08:56:00">[08:56:00]</a>. Stakeholders must take responsibility in their areas of expertise <a class="yt-timestamp" data-t="09:21:00">[09:21:00]</a>.
*   **Broad Expertise and Multi-level Involvement** <a class="yt-timestamp" data-t="17:25:00">[17:25:00]</a>: Including a diverse mix of expertise at different levels—from office work to advisory boards and healthcare sector involvement—is vital <a class="yt-timestamp" data-t="17:25:00">[17:25:00]</a>.
*   **Structured Partnerships** <a class="yt-timestamp" data-t="23:39:00">[23:39:00]</a>:
    *   **Clear Legal and IP Frameworks** <a class="yt-timestamp" data-t="23:47:00">[23:47:00]</a>: Establishing these early helps align expectations and overcome initial distrust <a class="yt-timestamp" data-t="24:42:00">[24:42:00]</a>.
    *   **Professional Alliance Management** <a class="yt-timestamp" data-t="24:55:00">[24:55:00]</a>: Dedicated professionals are needed to manage large, complex multi-stakeholder initiatives, as researchers alone cannot handle them <a class="yt-timestamp" data-t="24:55:00">[24:55:00]</a>. This expertise helps overcome personalities and egos to foster team work <a class="yt-timestamp" data-t="46:53:00">[46:53:00]</a>.
    *   **Clear Work Plans** <a class="yt-timestamp" data-t="24:45:00">[24:45:00]</a>: Ensuring every player understands their role and responsibilities <a class="yt-timestamp" data-t="24:45:00">[24:45:00]</a>.
*   **Neutral Arenas and Leadership** <a class="yt-timestamp" data-t="29:27:00">[29:27:00]</a>: Providing a neutral environment with neutral leadership can help overcome difficulties in partnerships, especially between regulators and regulated entities <a class="yt-timestamp" data-t="29:27:00">[29:27:00]</a>.
*   **Agile Approach and Demonstrators** <a class="yt-timestamp" data-t="30:10:00">[30:10:00]</a>: Adopting an agile approach allows for adaptability over time <a class="yt-timestamp" data-t="30:10:00">[30:10:00]</a>. Focusing on case-based work and building demonstrators (e.g., Vision Zero Cancer starting with lung cancer) can show the potential for full system transformation without trying to change everything at once <a class="yt-timestamp" data-t="31:01:00">[31:01:00]</a>.
*   **Long-term Perspective** <a class="yt-timestamp" data-t="30:45:00">[30:45:00]</a>: Recognizing that these projects are long-term and require sustained funding and evaluation over extended periods <a class="yt-timestamp" data-t="32:21:00">[32:21:00]</a>.
*   **Patient Engagement** <a class="yt-timestamp" data-t="17:46:00">[17:46:00]</a>: Patient and relative involvement in all steps is crucial <a class="yt-timestamp" data-t="17:46:00">[17:46:00]</a>. This includes gathering patient-reported experiences and outcomes, and utilizing platforms for online monitoring and information exchange <a class="yt-timestamp" data-t="33:41:00">[33:41:00]</a>.
*   **Learning from Other Initiatives** <a class="yt-timestamp" data-t="26:47:00">[26:47:00]</a>: Drawing lessons from similar initiatives like the European Active and Healthy Aging initiative, which successfully brought together diverse sectors like healthcare, social care, food, and transport companies <a class="yt-timestamp" data-t="26:47:00">[26:47:00]</a>.
*   **Policy and Administration Alignment** <a class="yt-timestamp" data-t="40:50:00">[40:50:00]</a>: Understanding and addressing administrative systems, leadership within healthcare, and the public administration structure are key to effective implementation <a class="yt-timestamp" data-t="40:50:00">[40:50:00]</a>.

## Examples of Collaboration

*   **Innovative Medicines Initiative (IMI) / Innovative Health Initiative (IHI)** <a class="yt-timestamp" data-t="21:54:00">[21:54:00]</a>: A €10 billion endeavor, jointly funded by the European Commission and industry (via in-kind contributions), focusing on catalyzing oncology R&D <a class="yt-timestamp" data-t="22:13:00">[22:13:00]</a>. These projects involve hundreds of partners from academia, industry, SMEs, and philanthropy <a class="yt-timestamp" data-t="23:04:00">[23:04:00]</a>.
*   **Genomic Medicine Sweden Network** <a class="yt-timestamp" data-t="18:10:00">[18:10:00]</a>: An initiative demonstrating successful multi-stakeholder engagement for implementing precision medicine in healthcare <a class="yt-timestamp" data-t="19:00:00">[19:00:00]</a>.
*   **Vision Zero Cancer Initiative** <a class="yt-timestamp" data-t="29:52:00">[29:52:00]</a>: Supported by Vinnova (the Swedish innovation agency), this program adopts an agile, vision-driven approach to innovation, starting with lung cancer to address systemic innovation aspects in a scalable way <a class="yt-timestamp" data-t="30:41:00">[30:41:00]</a>.
*   **Comprehensive Cancer Centers** <a class="yt-timestamp" data-t="11:18:00">[11:18:00]</a>: These integrated centers combine research, education, and healthcare, providing a strong infrastructure background essential for personalized medicine and translational research focused on patient needs <a class="yt-timestamp" data-t="39:57:00">[39:57:00]</a>.
*   **COVID-19 Pandemic Response** <a class="yt-timestamp" data-t="48:08:00">[48:08:00]</a>: The rapid development and distribution of COVID-19 therapies demonstrated Europe's ability to act together with a sense of urgency and willingness, proving that large-scale, multi-stakeholder collaboration is achievable <a class="yt-timestamp" data-t="48:08:00">[48:08:00]</a>.